Sp1004

ROLE OF HRM FOLLOWING FUNDOPLICATION

Date
May 21, 2024

Presenters

Speaker Image for Jutta Keller
Speaker Image for Sumeet Mittal
creighton university

Tracks

Related Products

Thumbnail for ENDOSCOPIC ASSESSMENT OF FAILED FUNDOPLICATIONS IS DEFINITIVELY DIFFERENT BETWEEN ENDOSCOPISTS
ENDOSCOPIC ASSESSMENT OF FAILED FUNDOPLICATIONS IS DEFINITIVELY DIFFERENT BETWEEN ENDOSCOPISTS
The aim of this study was to assess the association between interval between nCRT and
Thumbnail for DISCUSSION
Thumbnail for LAPAROSCOPIC REPAIR OF SLIPPED NISSEN FUNDOPLICATION
LAPAROSCOPIC REPAIR OF SLIPPED NISSEN FUNDOPLICATION
53-year-old female with a past medical history of hypertension, hiatal hernia and gastroesophageal reflux disease (GERD) presented with daily heartburn (improved by PPIs), regurgitation, and chronic cough. Upper endoscopy revealed 7 cm hiatal hernia, LA class C esophagitis and hill-grade 3-4…
Thumbnail for SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…